The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the ...

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...

Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat adults with transthyretin amyloid cardiomyopathy ...

A single IV infusion of nexiguran ziclumeran (nex-z), a therapy that targets production of TTR in the liver, was delivered to patients (n=36) with ATTR-CM, explained Marianna Fontana, MD ...

UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...

Attruby is an oral drug designed to treat transthyretin amyloid cardiomyopathy, or ATTR-CM, which is a form of amyloidosis that is currently underdiagnosed and is caused by the destabilization of ...

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial ...

Acoramidis is a selective small molecule, orally administered near-complete transthyretin stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive ...

The ATTRibute-CM Phase III trial, which formed the basis for the FDA's approval, enrolled 632 subjects with symptomatic ATTR-CM. Participants were randomised in a 2:1 ratio to receive either ...